1. Home
  2. LEGN vs FRHC Comparison

LEGN vs FRHC Comparison

Compare LEGN & FRHC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LEGN
  • FRHC
  • Stock Information
  • Founded
  • LEGN 2014
  • FRHC 1981
  • Country
  • LEGN United States
  • FRHC United States
  • Employees
  • LEGN N/A
  • FRHC N/A
  • Industry
  • LEGN Biotechnology: Pharmaceutical Preparations
  • FRHC Investment Bankers/Brokers/Service
  • Sector
  • LEGN Health Care
  • FRHC Finance
  • Exchange
  • LEGN Nasdaq
  • FRHC Nasdaq
  • Market Cap
  • LEGN 7.0B
  • FRHC 7.8B
  • IPO Year
  • LEGN 2020
  • FRHC N/A
  • Fundamental
  • Price
  • LEGN $28.91
  • FRHC $169.00
  • Analyst Decision
  • LEGN Strong Buy
  • FRHC
  • Analyst Count
  • LEGN 13
  • FRHC 0
  • Target Price
  • LEGN $75.67
  • FRHC N/A
  • AVG Volume (30 Days)
  • LEGN 1.7M
  • FRHC 101.2K
  • Earning Date
  • LEGN 05-13-2025
  • FRHC 06-13-2025
  • Dividend Yield
  • LEGN N/A
  • FRHC N/A
  • EPS Growth
  • LEGN N/A
  • FRHC N/A
  • EPS
  • LEGN N/A
  • FRHC 5.36
  • Revenue
  • LEGN $728,303,000.00
  • FRHC $1,578,152,000.00
  • Revenue This Year
  • LEGN $64.21
  • FRHC N/A
  • Revenue Next Year
  • LEGN $53.69
  • FRHC N/A
  • P/E Ratio
  • LEGN N/A
  • FRHC $31.55
  • Revenue Growth
  • LEGN 112.46
  • FRHC 79.07
  • 52 Week Low
  • LEGN $27.34
  • FRHC $71.88
  • 52 Week High
  • LEGN $60.87
  • FRHC $185.00
  • Technical
  • Relative Strength Index (RSI)
  • LEGN 39.95
  • FRHC 62.09
  • Support Level
  • LEGN $28.14
  • FRHC $138.99
  • Resistance Level
  • LEGN $31.12
  • FRHC $185.00
  • Average True Range (ATR)
  • LEGN 1.87
  • FRHC 5.31
  • MACD
  • LEGN -0.16
  • FRHC 0.70
  • Stochastic Oscillator
  • LEGN 25.95
  • FRHC 58.97

About LEGN Legend Biotech Corporation

Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's lead product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.

About FRHC Freedom Holding Corp.

Freedom Holding Corp is a holding company with its subsidiary it is engaged in securities brokerage, securities dealing for customers and account, market-making activities, investment research, investment counseling, investment banking services, retail and commercial banking, insurance products, payment services, and information processing services. It acts as a professional participant through its subsidiaries on the Kazakhstan Stock Exchange (KASE), Moscow Exchange (MOEX), Saint-Petersburg Exchange (SPB), the Ukrainian Exchange, the Uzbek Republican Currency Exchange (UZCE), and the Republican Stock Exchange of Tashkent (UZSE). Its segments are Brokerage, Banking, Insurance, and Others.

Share on Social Networks: